SCOPE Community E-meeting: Developments in the HIV and STIs biomedical prevention pipeline
The European AIDS Treatment Group, along with European and local organizations are coming together for a virtual meeting via Zoom e-meeting on Wednesday, May 24 at 6:00 to 7:30 AM ET (12:00 – 13:30 PM CET).
This interactive e-meeting for community educators and advocates will provide an update on the latest developments in biomedical HIV and STIs prevention research and implementation, new approaches and future challenges. Participants will learn from each other and discuss community preferences, uptake and access issues, as well as advocacy efforts to overcome policy and financial barriers at local, regional and European level. Live interpretation in English and Russian will be provided. This meeting is part of the SCOPE Project.
Avac Event
STI & HIV World Congress (ISSTDR) 2023
The STI & HIV World Congress (also known as ISSTDR) kicks off in Chicago, Illinois, USA and AVAC will be there. This is the first major face-to-face meeting of STI & HIV professionals since 2019 and one of the only spaces the global STI community comes together to promote ongoing STI research efforts and exchange information on current investigations. This is also the first time AVAC is attending ISSTDR in hopes of expanding STI advocacy and community engagement.
Follow events in real time with the official hashtag, #STIHIV2023, AVAC will offer comments and updates on Twitter.
Visit STIWatch.org, a new resource for the sexual and reproductive health and rights (SRHR) community to better understand and advocate for STI vaccine and diagnostics research, development and rollout.
STI & HIV World Congress 2023 Roadmap
Check out some AVAC-featured sessions below.
The STI Prevention Pipeline: Where Are We, and What Will It Take to Move Forward Faster? Monday, July 24 11:00 AM to 2:00 PM in the Cadmium Room Join us to explore the current development and implementation stages of STI vaccines and diagnostics and identify ways to accelerate research through advocacy.
Symposium: New Vaccine Approaches to STI Prevention STI Vaccine Acceptance and Equity Tuesday, July 25 2:30 PM to 4:00 PM in Chicago 6 Join AVAC’s Alison Footman to dive into the topic of STI vaccines and equity as new interventions come into reach.
Setting Up a Remote/Home Testing STI Programme: A Practical Toolkit Thursday, July 25 11:30 AM to 1:00 PM in Sheraton IV/V Room Join us to explore the power of remote testing to affordably curb STI acquisitions.
Community Happy Hour Monday, July 24, 6:00 to 8:00 PM at Lizzie McNeill’s Join AVAC and partners for a no frills happy hour for the STI community. All are welcome!
ISSTDR Advocacy Zone Monday, July 24 to Thursday, July 27 at the Exhibit Hall Visit the Advocacy Zone, a space to ask important questions, connect with fellow STI advocates, and begin to chart next steps in advancing STI R&D.
Avac Event
Private Sector Delivery Opportunities for the Dual Prevention Pill (DPP)
Lessons from family planning (FP) for the introduction of multi-purpose prevention technologies (MPTs)
The Dual Prevention Pill (DPP) is a daily pill being developed for simultaneous pregnancy and HIV prevention. With anticipated rollout of the DPP just two years away, planning for where to introduce the DPP in the private sector will be critical for ensuring access, but will hinge on where PrEP delivery is already permitted.
In this webinar, we shared new findings on private sector opportunities for the DPP in Kenya, South Africa and Zimbabwe. We explored lessons and successes from the FP experience to identify how FP/SRH stakeholders can help pave the way for smooth introduction of MPTs like the DPP in private sector channels.
Consultation with FP/SRH Stakeholders on the Dual Prevention Pill (DPP)
On April 12, AVAC and FP2030 convened a consultation with family planning (FP) and sexual and reproductive health (SRH) stakeholders to understand their unique perspectives on the Dual Prevention Pill (DPP), a daily pill that prevents HIV and pregnancy. The consultation focused on key issues that must inform plans for DPP introduction plans and the development and delivery of future multi-purpose prevention technologies (MPTs).
Jessica Rodrigues (AVAC) presented an overview of the DPP in the context of MPTs and highlighted progress to date and key milestones for research and development, evidence generation and market preparation
Barbara Friedland (Population Council) outlined key questions and complexities on potential demand for DPP, the DPP in the FP landscape and aligning PrEP & COC counseling guidance
Danny Edwards and Dani Resar (CHAI) discussed systems considerations for DPP (and future MPT) introduction, with a focus on procurement of the DPP by FP agencies/organizations and adaptations needed to support M&E planning for the DPP
Beth Fredrick (Johns Hopkins Bloomberg School of Public Health) facilitated a discussion featuring audience perspectives on potential opportunities and challenges for the DPP
Mande Limbu and Hima Patel (FP2030) opened and closed the webinar
Can Fantasies Become Realties? The Quest for Multi-purpose Prevention Products
On October 13, 2021, the AIDS Foundation of Chicago (AFC) and AVAC hosted Can Fantasies Become Realties? The Quest for Multi-purpose Prevention Products, a webinar featuring global expert Dr. Sharon Hillier and others. They discussed the need for products that not only prevent HIV but are contraceptive as well, or prevent other STIs – or all of the above. Fascinating science is currently underway, with some new interventions getting closer to prime time. Like the previous webinars in this series (Butt Stuff and Pleasure Buffet) – there was a DJ and also performers.
What’s Your Pleasure? Expanding Your Choices on the HIV Prevention Buffet
On Tuesday, 29 June 2021, the AIDS Foundation Chicago, along with community sponsors AVAC, Black AIDS Institute, Desmond Tutu Health Foundation and SisterLove, Inc., held a webinar featuring global HIV prevention research experts coupled with spoken word artistry and a smokin’ DJ (yes, a DJ!). The webinar provided a scientific update on the expansive HIV prevention research pipeline, including a wide array of molecules and modalities as well as multi-purpose technologies, from Desmond Tutu Health Foundation’s Dr. Linda-Gail Bekker. Seasoned community advocates Dazon Dixon Diallo of SisterLove (Atlanta, Johannesburg) and Black AIDS Institute’s Rob Newells (Atlanta) gave their perspectives on the pipeline with a focus on Black cisgender and transgender women and Black gay, same gender loving, and bisexual men.
Smokin’ beats courtesy of DJ Triple D and spoken word by Storie Devereaux.
Any questions, please reach out to Jim Pickett at [email protected].
Avac Event
Developing Dual Compartment Multipurpose Prevention Technologies That Work Up Front and From Behind
The development of multipurpose prevention technologies (MPTs) has emerged in recent years as a leading strategy to improve sexual and reproductive health outcomes. José Fernández Romero, a Population Council virologist, discussed the importance of MPTs designed to target different viral sexually transmitted infections and formulated for use in both vaginal and rectal compartments.
Click below to download the presentation slides.
Avac Event
What do women want in multipurpose technologies?
Multipurpose Prevention Technologies (MPTs) are a fast-growing area in women’s sexual and reproductive health. On November 12, AVAC and CAMI Health co-hosted a webinar: MPT Acceptability in Uganda, Nigeria and South Africa.
The webinar summarzied methods and key findings from the market research study conducted by Ipsos Healthcare, with support from the Bill & Melinda Gates Foundation, to assess the acceptability of multipurpose options among women in Uganda, Nigeria and South Africa.
The webinar discussed:
What women in Uganda, Nigeria and South Africa shared about sexual behavior, contraceptives and HIV prevention needs—and how this information will be used to shape the MPT agenda.
What the research found about the acceptability of four potential MPTs (injectables, implants, intra-vaginal film, intra-vaginal ring).
Jeff Lucas and Moushira El-Sahn from Ipsos Healthcare summarized methods and key findings from the market research data, and Bethany Young-Holt from CAMI Health moderated the discussion.
This call was one of the latest updates in the MPT field. Here are some other resources of note:
Two weeks ago, the journal BJOG: An international Journal of Obstetrics and Gynaecologypublished a suite of articles (all open access) on the future of “multipurpose” options that would provide both contraception and protection against HIV and/or other sexually transmitted infections. It is a strong series of updates related to the science and policy of new product development and an excellent overview of the state of play of this critical area of work.
Multiple MPT products are in the pipeline. See AVAC’s infographic, MPT Products in the Pipeline: Selected Highlights, that summarizes which MPTs are further along in testing for both sustained-release and on-demand products.
Avac Event
Exploring the Pipeline: Lubes, Rings, Films, Fibers, and Shots 4 HIV Prevention
AIDS Foundation of Chicago’s Jim Pickett and Jessica Terlikowski, presented Project Ready, Set, PrEP Plus (RSP+), a webinar on the research and development pipeline of new HIV prevention tools. New forms of PrEP were discussed – from lubricants and gels to injections, films, fibers, rectal douches and rings.
Avac Event
Global launch of the G-FINDER 2014 Reproductive Health report
Report co-author, Dr Mary Moran, and international key commentators discussed the report’s findings and health funding decisions for the future. The first G-FINDER Reproductive Health survey reported 2013 global investment into research and development (R&D) for new reproductive health products for developing countries. It covered investment for post-partum haemorrhage, contraceptives, non-HIV STIs, multipurpose prevention technologies and platform technologies. The G-FINDER Reproductive Health survey is conducted by the independent research group Policy Cures and is funded by the Bill & Melinda Gates Foundation. For more information regarding G-FINDER and Policy Cures, visit www.policycures.org or contact [email protected].